Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A known ✓ | Q12879 | 2/20 | 0.47 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.47 |
| ▸ | NOS2 | P35228 | 4/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.47 |
| ▸ | NOS1 | P29475 | 4/20 | 0.41 |
| ▸ | NOS3 | P29474 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6191953 | 0.98 | NOS2 (0.61) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL6192352 | 0.96 | NOS2 (0.59) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| SCHEMBL1230273 | 0.80 | NOS2 (0.67) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| SCHEMBL22068858 | 0.79 | NOS2 (0.65) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| SCHEMBL22068857 | 0.79 | NOS2 (0.65) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| SCHEMBL104888 | 0.79 | NOS2 (0.65) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL4003818 | 0.78 | NOS2 (0.64) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| SCHEMBL20675953 | 0.76 | NOS2 (0.96) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| SCHEMBL14291059 | 0.76 | NOS2 (0.96) | NOS2GRIN2BGRIN1GRIN2DGRIN3B | |
| SCHEMBL987917 | 0.74 | GRIN2B (0.59) | NOS2GRIN2BGRIN1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| US-7354929-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-20070105856-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER INC | 2007-05-10 | — | — | US | disclosed |
| US-7141669-B2 | Cannabiniod receptor ligands and uses thereof | PFIZER INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1622902-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004094417-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040214838-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | GRIN2A 2864/4885SIGMAR1 1494/4885NOS2 367/4885 |
| US-20070105856-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | GRIN2A 161/4885SIGMAR1 133/4885NOS2 3713/4885 |
| US-20040214838-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | GRIN2A 139/4885SIGMAR1 102/4885NOS2 3764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.